Skip to main content
Guanhao Biotech Co., Ltd logo

Guanhao Biotech Co., Ltd — Investor Relations & Filings

Ticker · 300238 ISIN · CNE100001575 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,710 across all filing types
Latest filing 2026-03-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300238

About Guanhao Biotech Co., Ltd

https://www.guanhaobio.com

Guanhao Biotech Co., Ltd. specializes in the research, development, and commercialization of regenerative medicine and biomaterial-based medical devices. The company focuses on tissue engineering and the production of high-tech implants designed to repair or replace damaged human tissues. Its core product portfolio includes biological patches for neurosurgery, such as dura mater repair patches, as well as solutions for ophthalmology, including corneal repair materials. Utilizing advanced processing technologies for animal-derived materials, the company creates biocompatible scaffolds that facilitate natural tissue regeneration while minimizing immunological rejection. Guanhao Biotech serves clinical needs across various surgical specialties, including orthopedics and wound management, by providing innovative surgical meshes and regenerative matrices. Its commitment to biotechnological innovation supports the advancement of reconstructive surgeries.

Recent filings

Filing Released Lang Actions
内部审计制度（2026年3月）
Governance Information Classification · 95% confidence The document is titled '内部审计制度' which translates to 'Internal Audit System' or 'Internal Audit Policy' of the company. It details the internal audit framework, responsibilities, procedures, and governance within the company. It does not contain financial statements, audit opinions from external auditors, or results of external audits. It is a policy or governance document related to internal audit processes rather than an audit report or annual report. It is not an announcement or a brief notice but a detailed internal governance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including internal audit policies.
2026-03-25 Chinese
2025年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" (Internal Control Audit Report) and includes detailed audit opinions on the effectiveness of the company's internal control over financial reporting as of December 31, 2025. It is issued by a certified public accounting firm and includes an evaluation of internal control deficiencies, both financial and non-financial, with no major defects found. The document also contains a comprehensive internal control evaluation report covering governance, risk control, human resources, financial accounting, fundraising, investment activities, product quality, procurement, sales, asset management, contract management, related party transactions, external guarantees, information disclosure, information systems, and subsidiary management. The document is about the audit and evaluation of internal controls rather than a full annual report or interim financial report. It is a standalone audit report focusing on internal control audit results and related disclosures. Therefore, it fits the category of Audit Report / Information (AR). The document length (9516 characters) is sufficient to be the report itself, not just an announcement. No evidence suggests it is a certification letter or a regulatory filing. Hence, the classification is AR with high confidence.
2026-03-25 Chinese
董事、高管薪酬管理制度（2026年3月）
Remuneration Information Classification · 95% confidence The document is titled as a remuneration management system for directors and senior management of the company. It details the principles, structure, decision-making procedures, and rules regarding compensation and incentives for board members and executives. There is no financial data, no report of financial results, no voting results, no legal proceedings, no capital changes, and no meeting materials. The content is focused on compensation policies and governance related to remuneration. This matches the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2026-03-25 Chinese
独立董事提名人声明与承诺
Board/Management Information Classification · 95% confidence The document is a detailed statement and commitment from a nominator regarding the nomination of an independent director candidate for the company's board. It includes qualifications, compliance with laws and regulations, and various declarations about the nominee's independence and eligibility. There is no financial data, no report of voting results, no announcement of a meeting, nor any financial or operational performance information. This document is related to board/management information, specifically about a board nomination and related declarations. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 3235 characters, which is consistent with a detailed declaration rather than a full report or announcement.
2026-03-25 Chinese
2025年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) issued by 大信会计师事务所 (WUYIGE Certified Public Accountants LLP) for 冠昊生物科技股份有限公司. It contains detailed audit opinions, basis for audit opinions, key audit matters such as revenue recognition and accounts receivable impairment, responsibilities of management and auditors, and extensive financial statement notes for the fiscal year ending December 31, 2025. The content is a standalone audit report with no indication that it is merely an announcement or certification. It includes detailed audit procedures and findings, consistent with an Audit Report / Information filing rather than a full Annual Report or other categories. Therefore, the document fits the definition of an Audit Report / Information (AR).
2026-03-25 Chinese
关于提请股东会授权董事会办理以简易程序向特定对象发行股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding a proposal to the shareholders to authorize the board of directors to handle a simplified procedure for issuing shares to specific investors. It details the authorization content, issuance conditions, pricing, lock-up period, use of funds, and procedural authorizations. The document is a formal announcement about a capital raising plan requiring shareholder approval, not the actual issuance or financial report. It does not contain financial statements or results but is focused on the capital issuance process and shareholder authorization. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 3608 characters, which is consistent with an announcement rather than a full report.
2026-03-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.